0001140361-24-024125.txt : 20240502 0001140361-24-024125.hdr.sgml : 20240502 20240502181923 ACCESSION NUMBER: 0001140361-24-024125 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240501 FILED AS OF DATE: 20240502 DATE AS OF CHANGE: 20240502 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: USMAN NASSIM CENTRAL INDEX KEY: 0001206872 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-51173 FILM NUMBER: 24910168 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: GYRE THERAPEUTICS, INC. CENTRAL INDEX KEY: 0001124105 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 562020050 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 12770 HIGH BLUFF DRIVE, SUITE 150 CITY: SAN DIEGO STATE: CA ZIP: 92130 BUSINESS PHONE: (619) 949-3681 MAIL ADDRESS: STREET 1: 12770 HIGH BLUFF DRIVE, SUITE 150 CITY: SAN DIEGO STATE: CA ZIP: 92130 FORMER COMPANY: FORMER CONFORMED NAME: CATALYST BIOSCIENCES, INC. DATE OF NAME CHANGE: 20150820 FORMER COMPANY: FORMER CONFORMED NAME: TARGACEPT INC DATE OF NAME CHANGE: 20000919 4 1 form4.xml FORM 4 X0508 4 2024-05-01 0001124105 GYRE THERAPEUTICS, INC. GYRE 0001206872 USMAN NASSIM C/O GYRE THERAPEUTICS, INC. 12770 HIGH BLUFF DRIVE, SUITE 150 SAN DIEGO CA 92130 true true Common Stock 2024-05-01 4 M 0 20000 6.93 A 21636 D Common Stock 2024-05-01 4 S 0 14900 13.86 D 6736 D Common Stock 2024-05-01 4 S 0 5000 14.9 D 1736 D Common Stock 2024-05-01 4 S 0 100 15.63 D 1636 D Common Stock 563 I By The Usman Family Trust Common Stock 77 I By Nassim Usman IRA Stock Option (Right to Buy) 6.93 2024-05-01 4 M 0 20000 0 D 2033-10-31 Common Stock 20000 281652 D This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on December 12, 2023. The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $13.50 to $14.44. Upon request by the staff of the U.S. Securities and Exchange Commission (the "Commission"), the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $14.50 to $15.32. Upon request by the staff of the Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. This option is vested in full. /s/ Ruoyu Chen, as attorney-in-fact for Nassim Usman 2024-05-02